Aspo Plc: Share Repurchase 13.3.2023
|Aspo Plc||Announcement 13.3.2023|
|Aspo Plc: Share Repurchase 13.3.2023|
|In the Helsinki Stock Exchange|
|Average price/ share||8.1704||EUR|
|Aspo Plc now holds a total of 69 344 shares|
|including the shares repurchased on 13.3.2023|
|On behalf of Aspo Plc|
|Nordea Bank Oyj|
|Janne Sarvikivi||Sami Huttunen|
|Further information, please contact:|
|Arto Meitsalo, CFO, Aspo Plc, tel. +358 40 5511 422, email@example.com|
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Indkaldelse til ordinær generalforsamling i EAC Invest A/S - Selskabsmeddelelse nr. 2/202331.3.2023 10:58:37 CEST | pressemeddelelse
København, 31. marts 2023 Den ordinære generalforsamling i EAC Invest A/S vil blive afholdt fredag den 28. april 2023 kl. 11:00 i Asia House, Indiakaj 16, 2100 København Ø. Vedhæftet dagsorden med bilag. Med venlig hilsen, for EAC Invest A/S Bestyrelsen For yderligere information Kresten M. Valdal, CEO,Telefon: +45 82334044, e-mail firstname.lastname@example.org Vedhæftede filer EAC Invest AS - AGM 2023 IndkaldelseEAC Invest AS - AGM 2023 - Bilag 1 - Bestyrelseskandidater2023.02 Indkaldelse til ordinær generalforsamling i EAC Invest AS
Decisions of Innofactor Plc’s Annual General Meeting and the organizing meeting of the Board of Directors31.3.2023 10:20:00 CEST | Press release
Innofactor Plc Stock Exchange Release March 31, 2023, at 11.20 Finnish time Adopting the accounts and the group's financial statement and granting the members of the Board of Directors and the Chief Executive Officer discharge from liability The Annual General Meeting (AGM) of Innofactor Plc held on March 31, 2023, resolved to adopt the accounts and the group's financial statement for the financial period that ended on December 31, 2022, and granted the members of the Board of Directors and the Chief Executive Officer discharge from liability for the financial period that ended on December 31, 2022. Deciding on the use of the profit shown on the balance sheet and the payment of dividend The AGM decided, in accordance with the proposal of the Board of Directors, that no dividend will be paid for the financial period of 2022. The AGM decided on a repayment of capital of EUR 0,06 per share to be paid. The repayment of capital shall be paid to shareholders who on the record date of the cap
AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 202231.3.2023 10:18:29 CEST | Press release
09:15 London, 11:15 Helsinki, 31 March 2023 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, OMX: AFAGR) Annual Financial Report AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 2022 Afarak Group announces that it has published today its Board of directors report, Financial Statement for the year 2022, the Auditor’s Report and the Corporate Governance Statement which is available from the Company's website www.afarak.com. Afarak publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the XHTML format labelled with XBRL tags, which are available as zip file attached to this release. A copy of the Board of Directors report and the Financial Statements for the year 2022 has been submitted to the UK's National Storage Mechanism. Afarak will hold its 2023 Annual General Meeting in Helsinki on within the time stipulated in the Finnish Companies Act. Helsinki 31 March 2023 Guy Konsbruck CEO For additional information,
Agillic named a leader in The Cross-Channel Marketing Hubs Landscape, Q1 2023 report by Independent Research Firm31.3.2023 10:02:56 CEST | Press release
Press release, Copenhagen, 31 March 2023 Agillic’s Omnichannel Marketing Automation Platform has been named in Forrester’s ‘The Cross-Channel Marketing Hubs Landscape, Q1 2023’ report as a notable vendor among CCMH vendor options for B2C marketing. The Forrester report for Cross-Channel Marketing Hubs (CCMHs) allows B2C executives to understand the value they can expect from a CCMH vendor, learn how vendors differ, and select the right one based on size and market focus. In the report, Forrester defines CCMHs as ‘Enterprise marketing technology that supports customer data management, analytics, segmentation, and workflow tools for designing, executing, and measuring marketing engagement across digital and offline channels.’ The overview recognises that B2C marketers are shifting their CCMH investments from traditional campaigns to investing more in providing customers with personalized and meaningful interactions. Marketers can use Cross-Channel Marketing Hubs, according to Forrester,
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates31.3.2023 10:00:42 CEST | Press release
SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB 1,453 million during 2022. Sales revenue from TUOYI® (toripalimab) alone was approximately RMB 736 million, representing an increase of approximately 79% compared to 2021. With the increase in commercialization capability, as well as the approval and launch of two more significant indications for TUOYI® in 2022, the company’s sales in the domestic market are gradually entering a positive cycle. Total research and development (“R&D”) expenses were approximately RMB 2,384 million in 2022, representing an increase of approximately 15% compared to 2021. The increase in R&D expenses